193 related articles for article (PubMed ID: 32286864)
1. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany.
Otremba B; Borchardt J; Kuske A; Hollnagel-Schmitz M; Losch FO
Future Oncol; 2020 May; 16(15):1001-1012. PubMed ID: 32286864
[No Abstract] [Full Text] [Related]
2. Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.
Shelbaya A; Kelton JM; Thompson J; Alvir JM; Maculaitis MC; Yang J
Future Oncol; 2021 Oct; 17(30):3941-3950. PubMed ID: 34259584
[TBL] [Abstract][Full Text] [Related]
3. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
McBride A; Daniel S; Driessen MT; Szende A; Choudhry A; Tian M; Ariely R; Thompson S
Leuk Res; 2021 Dec; 111():106671. PubMed ID: 34530254
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
5. Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India.
Nair R; Radhakrishnan VS; Mallath MK
Lancet Haematol; 2021 Aug; 8(8):e548-e549. PubMed ID: 34329574
[No Abstract] [Full Text] [Related]
6. Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data.
Roberto G; Spini A; Bartolini C; Moscatelli V; Barchielli A; Paoletti D; Giorgi S; Fabbri A; Bocchia M; Donnini S; Gini R; Ziche M
PLoS One; 2020; 15(3):e0229973. PubMed ID: 32163477
[TBL] [Abstract][Full Text] [Related]
7. Rituximab biosimilars for lymphoma in Europe.
Jurczak W; Długosz Danecka M; Buske C
Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
[No Abstract] [Full Text] [Related]
8. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
Coiffier B
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
[TBL] [Abstract][Full Text] [Related]
10. Rituximab biosimilars in hematologic malignancies: the need for a real-world approach.
Nava-Parada P; Shelbaya A; Nabhan C
Future Oncol; 2020 Sep; 16(26):2017-2027. PubMed ID: 32598173
[TBL] [Abstract][Full Text] [Related]
11. Safety of switching between rituximab biosimilars in onco-hematology.
Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
[TBL] [Abstract][Full Text] [Related]
12. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
[TBL] [Abstract][Full Text] [Related]
13. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
[TBL] [Abstract][Full Text] [Related]
14. A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.
Jo JC; Jeon Y; Kim D; Yang DH; Lee WS; Choi YS; Yi JH; Yoon DH; Kong JH; Choe JY; Kim S; Ahn K; Park T; Ju H; Kwon S; Cho SG
Expert Opin Biol Ther; 2023; 23(8):737-747. PubMed ID: 36757373
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
[TBL] [Abstract][Full Text] [Related]
17. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
Bishton M; Marshall S; Harchowal J; Salles G; Golfier C; Tucci A; Fernández AR; Sanchez Blanco JJ; Bocchia M; Kim S; Lee YN; Zinzani PL
Hematol Oncol; 2022 Aug; 40(3):370-380. PubMed ID: 35168291
[TBL] [Abstract][Full Text] [Related]
18. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
19. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.
Shi Y; Song Y; Qin Y; Zhang Q; Han X; Hong X; Wang D; Li W; Zhang Y; Feng J; Yang J; Zhang H; Jin C; Yang Y; Hu J; Wang Z; Jin Z; Su H; Wang H; Yang H; Fu W; Zhang M; Zhang X; Chen Y; Ke X; Liu L; Yu D; Chen G; Wang X; Jin J; Sun T; Du X; Cheng Y; Yi P; Zhao X; Ma C; Cheng J; Chai K; Luk A; Liu E; Zhang X
J Hematol Oncol; 2020 Apr; 13(1):38. PubMed ID: 32299513
[TBL] [Abstract][Full Text] [Related]
20. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
